Kenvue fights back against Tylenol safety concerns as its stock tumbles

Kenvue (KVUE) shares plunged a record 9.4% on Friday, closing at a 13-month low, following reports that U.S. HHS Secretary Robert F. Kennedy Jr. is expected to release a report linking prenatal acetaminophen use to autism. Kenvue swiftly responded, asserting that extensive scientific analysis and regulatory reviews, including by the FDA, have found no causal link. This significant selloff highlights potential regulatory and reputational risks for the consumer health sector, particularly given Kennedy's recent controversial actions regarding public health policy, with Kenvue's stock now down 12.8% year-to-date.

Analysis

Kenvue Inc. (KVUE) shares experienced a record 9.4% single-day decline to a 13-month low of $18.62, driven by news that the U.S. Department of Health and Human Services plans to release a report linking prenatal acetaminophen use to autism. This development poses a direct threat to Kenvue's flagship Tylenol brand and introduces significant litigation and reputational risk. In response, Kenvue has publicly stated that over a decade of scientific analysis and regulatory reviews by entities like the FDA have established no causal link. The market's severe reaction underscores the weight of this regulatory threat, which has exacerbated the stock's existing underperformance, now at a 12.8% loss year-to-date versus a 10.2% gain in the S&P 500. The situation is amplified by the broader context of HHS Secretary Robert F. Kennedy Jr.'s recent controversial actions, signaling a potentially more aggressive and unpredictable regulatory environment for the entire healthcare sector.

Key Decisions for Investors

• Investors should anticipate sustained share price volatility for Kenvue leading up to the expected September release of the HHS report, which represents a major binary risk event.
• It is critical to weigh Kenvue's defense, which is backed by existing scientific consensus and FDA reviews, against the substantial financial risk from potential class-action lawsuits and long-term brand damage that the market is currently pricing in.
• Given the stock's sharp decline, risk-tolerant investors may evaluate the valuation, but any position should be sized to reflect the high uncertainty and headline risk, which extends beyond Kenvue to the broader consumer health sector under the current regulatory leadership.